Physician profile
Robert Busch
NPI 1063466811
$2,346.94
in general payments reported to CMS, 2019-2025
30 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $306 · 2021: $371 · 2022: $165 · 2023: $228 · 2024: $462 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $384.23 | 2019-2025 | Titan |
| Antares Pharma, INC. | $254.77 | 2019-2025 | Xyosted |
| Axonics, INC. | $248.95 | 2020-2024 | Axonics |
| Astellas Pharma US INC | $206.13 | 2019-2021 | |
| Boston Scientific Corporation | $177.16 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $145.51 | 2019-2023 | Xiaflex |
| Tolmar, INC. | $99.42 | 2023-2025 | Eligard, Jatenzo |
| Neotract INC. | $88.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.57 | 2019-2024 | |
| Endo USA, INC. | $73.81 | 2025 | Xiaflex |
| Abc Home Medical Supply, INC. | $60.57 | 2022-2025 | |
| Laborie Medical Technologies Corp. | $60.07 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Sumitomo Pharma America, INC. | $52.05 | 2023-2024 | Gemtesa, Orgovyx |
| Clarus Therapeutics INC. | $46.98 | 2021 | |
| Civco Medical Instruments | $40.83 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $38.79 | 2025 | Urolift |
| Immunitybio, INC. | $32.25 | 2025 | |
| Urogen Pharma, INC. | $32.22 | 2025 | |
| Janssen Biotech, INC. | $29.29 | 2019 | |
| Myriad Genetic Laboratories, INC. | $27.78 | 2021-2023 | Prolaris |
| Azurity Pharmaceuticals, INC. | $20.88 | 2025 | Azmiro |
| Calyxo, INC. | $19.33 | 2025 | Cvac Aspiration System |
| Tolmar Pharmaceuticals, INC. | $18.36 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.37 | 2019 | |
| Rochester Medical Corporation | $15.89 | 2020 | |
| 180 Medical, INC. | $15.81 | 2020 | |
| Becton, Dickinson and Company | $15.34 | 2025 | Bard Urinary Drainage Bag |
| Novartis Pharmaceuticals Corporation | $14.17 | 2024 | |
| Halozyme INC | $13.56 | 2023 | |
| Verity Pharmaceuticals INC. | $13.20 | 2024 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.